Trial Outcomes & Findings for Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery (NCT NCT02836990)

NCT ID: NCT02836990

Last Updated: 2020-12-28

Results Overview

The primary effectiveness endpoint is 30 day healing of the randomized groin incision, with any wound infection or failure to heal. Szilagyi wound infection grade quantified on an ordinal scale will be used to assess the healing (None, Grade I: Infection contained to the dermis, Grade II: Infection extending into the subcutaneous tissue but the arterial graft is not involved, Grade III: Infection of the arterial graft or native vessel underlying the incision). Healing is assessed by complete sealing of the incision with no residual separation or drainage. All of the incisions were primarily closed, so a healed incision would have no gaps between the skin edges. This is a visual inspection. Szilagi is an assessment of the grade of wound infection for those that did not heal. It is well recognized and published, and noted as above for patients with vascular exposure.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

105 participants

Primary outcome timeframe

30 days

Results posted on

2020-12-28

Participant Flow

Participants were recruited from UBMD Vascular Surgery Office and were consented at the time of surgery at Buffalo General Medical Center between 2016 and 2019.

Participant milestones

Participant milestones
Measure
Prevena
Prevena Incision Management System for vascular surgical groin wounds Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
Dermabond
Dermabond for vascular surgical groin wounds Dermabond: A surgical skin adhesive used to prevent surgical wound infections
Overall Study
STARTED
50
55
Overall Study
COMPLETED
50
55
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Prevena
n=46 Participants
Prevena Incision Management System for vascular surgical groin wounds Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
Dermabond
n=55 Participants
Dermabond for vascular surgical groin wounds Dermabond: A surgical skin adhesive used to prevent surgical wound infections
Total
n=101 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=113 Participants
0 Participants
n=163 Participants
0 Participants
n=160 Participants
Age, Categorical
Between 18 and 65 years
16 Participants
n=113 Participants
20 Participants
n=163 Participants
36 Participants
n=160 Participants
Age, Categorical
>=65 years
30 Participants
n=113 Participants
35 Participants
n=163 Participants
65 Participants
n=160 Participants
Age, Continuous
68 years
STANDARD_DEVIATION 10 • n=113 Participants
68 years
STANDARD_DEVIATION 12 • n=163 Participants
68 years
STANDARD_DEVIATION 11 • n=160 Participants
Sex: Female, Male
Female
21 Participants
n=113 Participants
15 Participants
n=163 Participants
36 Participants
n=160 Participants
Sex: Female, Male
Male
25 Participants
n=113 Participants
40 Participants
n=163 Participants
65 Participants
n=160 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=113 Participants
0 Participants
n=163 Participants
0 Participants
n=160 Participants
Race (NIH/OMB)
Asian
0 Participants
n=113 Participants
0 Participants
n=163 Participants
0 Participants
n=160 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=113 Participants
0 Participants
n=163 Participants
0 Participants
n=160 Participants
Race (NIH/OMB)
Black or African American
10 Participants
n=113 Participants
4 Participants
n=163 Participants
14 Participants
n=160 Participants
Race (NIH/OMB)
White
36 Participants
n=113 Participants
51 Participants
n=163 Participants
87 Participants
n=160 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=113 Participants
0 Participants
n=163 Participants
0 Participants
n=160 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=113 Participants
0 Participants
n=163 Participants
0 Participants
n=160 Participants
Region of Enrollment
United States
46 participants
n=113 Participants
55 participants
n=163 Participants
101 participants
n=160 Participants

PRIMARY outcome

Timeframe: 30 days

The primary effectiveness endpoint is 30 day healing of the randomized groin incision, with any wound infection or failure to heal. Szilagyi wound infection grade quantified on an ordinal scale will be used to assess the healing (None, Grade I: Infection contained to the dermis, Grade II: Infection extending into the subcutaneous tissue but the arterial graft is not involved, Grade III: Infection of the arterial graft or native vessel underlying the incision). Healing is assessed by complete sealing of the incision with no residual separation or drainage. All of the incisions were primarily closed, so a healed incision would have no gaps between the skin edges. This is a visual inspection. Szilagi is an assessment of the grade of wound infection for those that did not heal. It is well recognized and published, and noted as above for patients with vascular exposure.

Outcome measures

Outcome measures
Measure
Prevena
n=46 Participants
Prevena Incision Management System for vascular surgical groin wounds Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
Dermabond
n=55 Participants
Dermabond for vascular surgical groin wounds Dermabond: A surgical skin adhesive used to prevent surgical wound infections
Comparison of Healing of Groin Wounds Between Patients Treated With Prevena vs Dermabond
41 Participants
54 Participants

SECONDARY outcome

Timeframe: 30 days

Population: not analyzed as the primary outcome did not demonstrate improved outcomes, and the device being tested, wound vacuum, was more expensive. Had outcomes clinically been improved, financial assessment would have determined whether cost of infection outweighed cost of device.

Comparison of cost of treatment between the two arms

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 30 days

Physician office visits for diagnosis of Infection or visiting nurse visits for diagnosis of infection ONLY were assessed.

Outcome measures

Outcome measures
Measure
Prevena
n=46 Participants
Prevena Incision Management System for vascular surgical groin wounds Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
Dermabond
n=55 Participants
Dermabond for vascular surgical groin wounds Dermabond: A surgical skin adhesive used to prevent surgical wound infections
Number of Visiting Nurses Home Visits and Physician Office Visits to Assess/Treat Wound Infection
7 Participants
7 Participants

Adverse Events

Prevena

Serious events: 3 serious events
Other events: 0 other events
Deaths: 0 deaths

Dermabond

Serious events: 2 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Prevena
n=46 participants at risk
Prevena Incision Management System for vascular surgical groin wounds Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
Dermabond
n=55 participants at risk
Dermabond for vascular surgical groin wounds Dermabond: A surgical skin adhesive used to prevent surgical wound infections
Infections and infestations
Reoperation for groin complication
6.5%
3/46 • Number of events 5 • 40 days from time of surgery
3.6%
2/55 • Number of events 2 • 40 days from time of surgery

Other adverse events

Adverse event data not reported

Additional Information

Dr Linda Harris

University at Buffalo, SUNY

Phone: 7168594207

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place